FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

4. None and Address of December Decemb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT O	F CHANGES IN	BENEFICIAL	OWNERSHIP

OMB Number: Estimated average burden hours per response: 0.5

5 Relationship of Reporting Person(s) to Issuer

OMB APPROVAL

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2 Issuer Name and Ticker or Trading Symbol

FINCK BARBARA K					Coherus BioSciences, Inc. [CHRS]												or (give title	.g . o	10% Ov Other (s	
	US BIOSCI	irst) IENCES, INC. IN DRIVE, SUI	(Middle) TE 600		3. Date of Earliest Transaction (Month/Day/Year) 07/09/2018								below	Chief Medical Officer						
(Street) REDWC	OOD C.	A	94065		4. If	f Am	endme	nt, Date	of C	Original	Filed	(Month/D	ay/Ye	ear)	6. l Lin	X Form	filed by One	e Rep	g (Check Ap orting Perso n One Repo	n
(City)	(S	tate)	(Zip)																	
1. Title of Security (Instr. 3) 2. Trans. Date							,	quired, Disposed of, or Bene 3. Transaction Code (Instr. 8) 4. Securities Acquired (. Disposed Of (D) (Instr. 3 5)			d (A) or	5. Amou Securiti Benefic	int of es ially Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Code	v	Amount	(A) or (D) Pr		Price	Transac (Instr. 3	tion(s)			, , ,	
Common	Stock, \$0.0	0001 par value		07/09	/2018	В				M		500		A	\$1.4	2 37	,543		D	
Common	Stock, \$0.0	0001 par value		07/09	/2018	8				S ⁽¹⁾		500		D	\$15.0	37	7,043 D			
Common	Stock, \$0.0	0001 par value		07/10	/2018	8				M		1,260)	A	\$1.4	2 38	38,303 D			
Common	Stock, \$0.0	0001 par value		07/10	/2018	В				S ⁽¹⁾		1,260)	D	\$15	37	,043 D			
		T										osed of onverti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	Pate, Transaction Code (Inst				Ex	6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		l Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly D	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Da:	ite ercisabl		expiration vate	Title	e	Amount or Number of Shares					
Stock Option (right to buy)	\$1.42	07/09/2018			М			500		(2)	1	1/23/2023		nmon ock	500	\$0.00	87,72	1	D	
Const.	I	I	I	- 1		1		1	1		- 1		I			I	I			1

Explanation of Responses:

\$1.42

- 1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- 2. The shares underlying this option are fully vested and exercisable as of the date hereof.

07/10/2018

Remarks:

Option

(right to buy)

/s/ Jean Frederic Viret, as Attorney in Fact for Barbara K. 07/11/2018 Finck, M.D.

\$0.00

** Signature of Reporting Person

1,260

Stock

Date

86,461

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

1,260

(2)

11/21/2023